Home | About IPJ | Editorial board | Ahead of print | Current Issue | Archives | Instructions | Contact us |   Login 
Industrial Psychiatry Journal
Search Articles   
    
Advanced search   
 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 25  |  Issue : 1  |  Page : 11-16

Clinical experience of baclofen in alcohol dependence: A chart review


1 Department of Psychiatry, SHKM Government Medical College, Nalhar, Haryana, India
2 Department of Psychiatry, SGT Hospital and Medical College, Gurgaon, Haryana, India
3 Department of Psychiatry, Government Medical College, Chandigarh, India

Correspondence Address:
Bir Singh Chavan
Department of Psychiatry, Government Medical College and Hospital, Sector 32, Chandigarh - 160 032
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-6748.196043

Rights and Permissions

Introduction: Craving is recognized as a formidable barrier in the management of patients with alcohol dependence. Among pharmacological agents that have been used in experimental studies for reduction in craving, baclofen appears to have a significant advantage over other agents. Methodology: The study is retrospective chart review of patients (n = 113) who have been treated with baclofen for alcohol dependence in a tertiary hospital of North India. Baseline assessments included sociodemography, motivation, quantity-frequency of alcohol use, and other alcohol-related clinical parameters. Weekly assessments, for a period of 4 weeks, were extracted from records which included dose of baclofen, craving intensity, and alcohol consumption. Results: The study sample was predominantly male, mean age of 41.49 (±9.75) years, most having a family history of substance use (70.97%), and many reporting binge use pattern in last year (49.46%). Baseline assessment revealed 48.7% of the sample was in precontemplation phase for alcohol use and 70% reported severe and persistent craving. This persistent craving was reported by only 15% of the sample by the end of 4 weeks treatment with baclofen (20–40 mg/day). Thirty-four percent of patients reported continued problematic use of alcohol by the end of 4 weeks. Conclusion: Our clinical experience suggests that baclofen reduces craving and alcohol consumption including in those with poor motivation. The drug causes few side effects and does not add to the intoxication effect of alcohol. Considering that baclofen is safe in those with liver cirrhosis and reduces withdrawal symptoms due to alcohol, a controlled trial comparing it with standard treatment is required.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1157    
    Printed44    
    Emailed0    
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal